DYADIC INTERNATIONAL INC Deferred Income Tax Expense (Benefit)
DYADIC INTERNATIONAL INC (DYAI) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2025-03-26
- DYADIC INTERNATIONAL INC deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- DYADIC INTERNATIONAL INC deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- DYADIC INTERNATIONAL INC deferred income tax expense (benefit) for fiscal 2020 was $0.00.
- DYADIC INTERNATIONAL INC deferred income tax expense (benefit) for fiscal 2019 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-30 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |